TITLE

Stability of extemporaneously prepared acetylcysteine 1% and 10% solutions for treatment of meconium ileus

AUTHOR(S)
Fohl, Alexander L.; Johnson, Cary E.; Cober, M. Petrea
PUB. DATE
January 2011
SOURCE
American Journal of Health-System Pharmacy;1/1/2011, Vol. 68 Issue 1, p69
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. The stability of extemporaneously prepared acetylcysteine 1% and 10% solutions for treatment of meconium ileus was evaluated. Methods. Acetylcysteine 1% (10-mg/ mL) and 10% (100-mg/mL) solutions were prepared by mixing 3 and 10 mL, respectively, of commercially available 20% acetylcysteine solution with a sufficient quantity of bacteriostatic 0.9% sodium chloride for injection to make a final volume of 60 mL. Three identical samples of each concentration were prepared, placed in 2-oz amber plastic prescription bottles, and stored at 20-25 °C. Samples were assayed in duplicate using high-performance liquid chromatography and inspected for changes in color, odor, and pH immediately after preparation and at 7, 14, 30, 60, and 90 days. Stability was defined as retention of at least 90% of the initial concentration. Results. At least 90% of the initial concentration of acetylcysteine was retained in both formulations for 60 days. No appreciable change from the initial pH occurred in the acetylcysteine 1% or 10% solution during the first 60 days, but there was a notable change in pH after 90 days in both formulations. Neither solution was stable at day 90. There was no detectable change in color at 90 days; however, the odor of hydrogen sulfide was more pungent than on previous study days. Conclusion. Extemporaneously prepared solutions of acetylcysteine 1% (10 mg/ mL) and 10% (100 mg/mL) prepared with bacteriostatic 0.9% sodium chloride for injection were stable for at least 60 days when stored in plastic amber bottles at room temperature.
ACCESSION #
56946549

 

Related Articles

  • Topical Aminolevulinic Acid HCl Photodynamic Therapy. Ormrod, D.; Jarvis, B. // American Journal of Clinical Dermatology;Mar/Apr2000, Vol. 1 Issue 2, p133 

    â–´ Photodynamic therapy (PDT) is the treatment of tumors or dysplasic tissue with drugs that produce cytotoxic metabolites when exposed to light. â–´ Aminolevulinic acid HCl (5-aminolevulinic acid HCl; ALA) is a prodrug that is metabolized intracellularly to form the photosensitizing...

  • Icatibant.  // Reactions Weekly;4/23/2011, Issue 1348/1349, p21 

    The article describes the case of a 61-year-old man with acquired angiodema who developed injection site reaction while receiving icatibant.

  • OF SPECIAL INTEREST.  // American Journal of Health-System Pharmacy;8/1/2015, Vol. 72 Issue 15, p1249 

    This section offers news briefs on the pharmaceutical profession in the U.S. as of August 1, 2015 on topics such as the replication of filtration procedures linked to Serratia marcescens bloodstream infections, the risks of sterile compounding, and the effects of cannabinoids on military...

  • Sermorelin: A Review of its Use in the Diagnosis and Treatment of Children with Idiopathic Growth Hormone Deficiency. Prakash, A.; Goa, K.L. // BioDrugs;1999, Vol. 12 Issue 2, p139 

    Sermorelin, a 29 amino acid analogue of human growth hormone-releasing hormone (GHRH), is the shortest synthetic peptide with full biological activity of GHRH. Intravenous and subcutaneous sermorelin specifically stimulate growth hormone secretion from the anterior pituitary. Hormone responses...

  • Spotlight on Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis. Simpson, Dene; Noble, Stuart; Perry, Caroline // BioDrugs;2003, Vol. 17 Issue 3, p207 

    Glatiramer acetate (Copaxone[sup ®]) is a synthetic copolymer composed of a random mixture of four amino acids that modifies the immune response that results in the CNS inflammation, demyelination and axonal loss characteristic of relapsing-remitting multiple sclerosis (RRMS). In three...

  • Topical Aminolevulinic Acid HCL: A Viewpoint by Peter Wolf. Wolf, P. // American Journal of Clinical Dermatology;Mar/Apr2000, Vol. 1 Issue 2, p140 

    Comments on the testing of aminolevulinic acid (ALA) in topical photodynamic therapy (PDT) for actinic keratosis on face and scalp in the United States. Details on the adverse effects of ALA PDT; Forms of PDT; Comparison between ALA PDT and topical chemotherapy with fluorouracil.

  • AMINO ACIDS TAKE ON CANCER.  // Joe Weider's Muscle & Fitness;May2001, Vol. 62 Issue 5, p52 

    Provides information on a study which examined the therapeutic use of amino acid glutamate as nutritional regimens to boost immune function and improve survival of cancer patients. Methods used; Findings and conclusion.

  • READY SET SHOP: SUPPLEMENTS. SEPTEMBER'S SUPER FINDS.  // Better Nutrition;Sep2010, Vol. 72 Issue 9, p16 

    The article evaluates multiple dietary supplements including Ashwagandha Root from Gaia Herbs, VM-100 Complete from Buried Treasure, and MemoryCell from Enzymedica.

  • STALKING SILK.  // Muscle & Performance;Jun2012, Vol. 4 Issue 6, p22 

    The article explains the health benefits of silk amino acids including enhanced endurance, muscle mass growth, and enhanced recovery from workouts.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics